We are eXmoor. A trusted, one-stop cell and gene therapy partner, accelerating the manufacturing journey from research to patients.
A safe pair of hands
Our team has more than 500 years’ collective experience of delivering innovative end to end GMP biomanufacturing projects, working across three continents.
Whether you are looking to commercialise a research process, develop a fully licensed facility or take your project from donation to delivery, pre-clinical to in-market supply, we are here to support you every step of the way.
Part of the team
From developing manufacturing strategies, processes and GMP facilities to ongoing QP support, we’re very proud of the business and the clients we work with.
We work as part of your team, providing a friendly and confidential service that meets your unique requirements. This approach has enabled us to develop lasting relationships with our clients based on trust and honest collaboration.
We look forward to working with you in the future
OUR SERVICES
eXmoor pharma experience
We listen. We put your interests first, by ensuring that what we do links with your business strategy. We value knowledge sharing and innovation – free thinking in a structured environment. We like to work as trusted members of an integrated, high performance team. We welcome feedback on our performance.
150+
CLIENTS
Over 150 CGT and biopharma clients
70%
REPEAT BUSINESS
Currently multiple projects with more than 70% of clients
516
INDIVIDUAL PROJECTS
eXmoor has completed over 500 cell therapy and biopharma projects
16
COUNTRIES
eXmoor has completed projects in 16 countries on 4 continents
500
YEARS’ COMBINED EXPERIENCE
eXmoor has a team with around 500 years’ combined experience
37
FACILITY DESIGNS
eXmoor has designed 37 cell & gene therapy and biopharma facilities globally
72
ISOLATORS
eXmoor has specified over 72 isolators for cell & gene therapy facilities globally
8
QP ROLES
eXmoor is currently named on the license as EU QP for 8 facilities
12
CLINICAL TRIALS
eXmoor is involved in 12 clinical trials
250
AMC
eXmoor co-founded the amc to build critical mass and share expertise in ATMP manufacturing; now with 250 fee paying members
OUR PROJECTS
“eXmoor has worked with us on the design and development of the Zayed Centre for Research into Rare Disease in Children GMP facility has provided huge input into the programme to ensure a GMP-compliant and well equipped facility for the future. They have guided us through the project with a friendly and highly professional service throughout. The resulting level of GMP compliance would not have been possible without their contribution.”
Head of QA, Gene Therapy at Great Ormond Street Hospital for Children NHS Foundation Trust
“We contracted eXmoor to rapidly perform a feasibility assessment on a potential expansion project we were interested in pursuing. The eXmoor team understood the business drivers for this approach and delivered a clear and well thought out package that really helped with our assessment of the opportunity.
The eXmoor team is very skilled, experienced and professional and were well placed to provide this early feasibility work, as well as more comprehensive packages of work to support more advanced projects.”
Senior Manager, UK Gene Therapy Company
“The most important thing for us is to work in partnership with our consultants and eXmoor really feels like a vital part of the team. Their client focused and agile approach to project management has meant that we can trust and rely on them to deliver the very best advice and solutions to meet our needs.
eXmoor draws on experience from many different disciplines including facility design and engineering, operational effectiveness and team structure. This has increased the value of everything they do for us as it feels like we are tapping into a wider team. In particular, their expertise in cell and gene therapy has been invaluable to us and we can’t thank them enough for their continued QP support, which is vital for our BDU, not just for product certification, but also for general GMP compliance questions.”
Head of Biotherapeutics Development Unit, Cancer Research UK